| Telmisartan: just an antihypertensive agent? A literature review. | |
| | |
MedLine Citation:
|
PMID: 22077832 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Introduction: The modulation of the renin angiotensin aldosterone system (RAAS) is an important pathway in managing high blood pressure, and its overexpression plays a key role in target end-organ damage. Telmisartan is an angiotensin II receptor blocker (ARB) with unique pharmacologic properties, including the longest half-life among all ARBs; this leads to a significant and 24-h sustained reduction of blood pressure. Telmisartan has well-known antihypertensive properties, but there is also strong clinical evidence that it reduces left ventricular hypertrophy, arterial stiffness and the recurrence of atrial fibrillation, and confers renoprotection. Areas covered: This paper reviews telmisartan's pharmacological properties in terms of efficacy for hypertension control and, importantly, focuses on its new therapeutic indications and their clinical implications. Expert opinion: ONTARGET (ongoing telmisartan alone and in combination with ramipril global endpoint trial) demonstrated, that telmisartan confers cardiovascular protective effects similar to those of ramipril, but with a better tolerability. Moreover, recent investigations focused on the capability of telmisartan to modulate the peroxisome proliferator-activated receptor-gamma (PPAR-?), an established target in the treatment of insulin resistance, diabetes and metabolic syndrome, whose activation is also correlated to anti-inflammatory and, finally, anti-atherosclerotic properties. Telmisartan shows peculiar features that go beyond blood pressure control. It presents promising and unique protective properties against target end-organ damage, potentially able to open a scenario of new therapeutic approaches to cardiovascular disease. |
| | |
Authors:
|
Maurizio Destro; Francesca Cagnoni; Giuseppina Patrizia Dognini; Vincenzo Galimberti; Carlo Taietti; Chiara Cavalleri; Emilio Galli |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 12 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-11-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 2719-35 Citation Subset: IM |
Affiliation:
|
General Medicine Unit, Treviglio?Caravaggio Hospital , Medical Department , A.O. Treviglio, 24047 Treviglio (BG) , Italy +39 03 6342 4251 ; +39 03 6342 4251 ; Maurizio_destro@ospedale.treviglio.bg.it. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Next Document: Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumo...